JANX
HEALTHCAREJanux Therapeutics Inc
AI Insight
What's Moving JANX Today?
No stock-specific AI insight has been generated for JANX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$12.12$35.34
$14.64
Fundamentals
Market Cap$892M
P/E Ratio—
EPS$-1.84
Dividend Yield—
Dividend / Share—
ROE-11.7%
Profit Margin—
Debt / Equity—
Trading
Volume1.5M
Avg Volume (10D)—
Shares Outstanding61.0M
JANX News
24 articles- Form 8K Janux Therapeutics Inc For: 23 June By Investing.comInvesting.com Australia·Jun 24, 2026
- B of A Securities Maintains Janux Therapeutics (JANX) Buy RecommendationMSN·Jun 7, 2026
- 4,059 RSUs to be Sold by JANX (NASDAQ: JANX)Stock Titan·Jun 3, 2026
- Akari Therapeutics Highlights 1st ASCO Abstract AcceptanceYahoo Finance·May 28, 2026
- VERAXA Biotech Secures $27.5M Financing, to Go Public Via SPACYahoo Finance·May 28, 2026
- Wall Street Analysts Predict a 155.82% Upside in Janux Therapeutics (JANX): Here's What You Should KnowYahoo Finance·May 28, 2026
- Here's Why You Should Add JANX Stock to Your Portfolio NowYahoo Finance·May 26, 2026
- What to Know About This Fund's $10 Million Nektar Bet Ahead of a Key Phase 3 LaunchMotley Fool·May 23, 2026
- This Healthcare Investor Added $43 Million to a Genomics Leader Growing Volume 34%Motley Fool·May 23, 2026
- How much upside is left in Janux Therapeutics (JANX)? Wall Street analysts think 180.44%MSN·May 13, 2026
- Milestone payment and strong cash fuel Janux (NASDAQ: JANX) pipelineStock Titan·May 8, 2026
- Janux Therapeutics, Inc. (JANX) Reports Q1 Loss, Lags Revenue EstimatesYahoo Finance·May 7, 2026
- Janux Therapeutics Reports First Quarter 2026 Financial Results and Business HighlightsYahoo Finance·May 7, 2026
- FDA claims Amgen drug data were ‘manipulated’; Erasca slides despite ‘home run’ resultsBiopharmadive·Apr 28, 2026
- Janux Therapeutics Announces Discontinuation of JANX008 Clinical DevelopmentYahoo Finance·Apr 27, 2026
- Lilly’s obesity pill off to a strong start; OpenAI debuts new drug discovery toolBiopharmadive·Apr 17, 2026
- Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014Yahoo Finance·Apr 16, 2026
- Will Health Benefits Weakness Drag Elevance's Q1 Earnings?Yahoo Finance·Apr 16, 2026
- Sector Update: Health Care Stocks Decline Late AfternoonYahoo Finance·Apr 15, 2026
- Sector Update: Health Care Stocks Lower in Afternoon TradingYahoo Finance·Apr 15, 2026
- Here Are Wednesday’s Top Wall Street Analyst Research Calls: Align Technology, American Tower, Autodesk, Autoliv, Chime Financial, Cloudflare, SolarEdge Technologies, Zoetis, and More247 Wall St·Apr 15, 2026
- Bristol-Myers Squibb Cancer Moves And Equity Efforts Underpin Valuation CaseYahoo Finance·Apr 3, 2026
- Janux Therapeutics Secures $35M Milestone Payment From BMY DealYahoo Finance·Apr 2, 2026
- Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration, Triggering $35 Million Milestone PaymentYahoo Finance·Apr 1, 2026
All 24 articles loaded
Price Data
Open$14.79
Previous Close$14.64
Day High$15.06
Day Low$14.60
52 Week High$35.34
52 Week Low$12.12
52-Week Range
$12.12$35.34
$14.64
Fundamentals
Market Cap$892M
P/E Ratio—
EPS$-1.84
Dividend Yield—
Dividend / Share—
ROE-11.7%
Profit Margin—
Debt / Equity—
Trading
Volume1.5M
Avg Volume (10D)—
Shares Outstanding61.0M
About Janux Therapeutics Inc
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapies based on the patented Tumor Activated T Cell Engager (TRACTr) platform technology to treat cancer patients. The company is headquartered in La Jolla, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—